COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				3 Months Ended
	Mar. 14, 2022	Mar. 07, 2022	Jan. 12, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Jun. 30, 2022
Annual license fee							$ 10,000
Annual royalty				$ 100,000
Professional fees				106,547	$ 133,483
Related Party [Member]
Accounts payable				630,489		$ 537,449
Massachusetts General Hospital [Member] | Related Party [Member]
Accounts payable				$ 18,364		375,000
License Agreement [Member]
License agreement, description				the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. As of March 31, 2024, the Company had yet to pay the second non-refundable license fee and is included in accounts payable, related party, on the unaudited consolidated balance sheet. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date. The Company has yet to generate any revenue as of the date of this filing.
License Agreement [Member] | Massachusetts General Hospital [Member]
License agreement, description				The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. $344 of expense reimbursements were paid to MGH during the three months ended March 31, 2024. No expense reimbursements were paid to MGH during the three months ended March 31, 2023. As of March 31, 2024, $18,364 is included in accounts payable, related parties, on the unaudited consolidated balance sheet.
Percentage for royalty				1.00%
Payment for related party	$ 1,000,000.0			$ 1,000,000.0
Expense reimbursements				344	0
License Agreement [Member] | Massachusetts General Hospital [Member] | Related Party [Member]
Accounts payable				18,364
Consulting Agreement [Member]
Expenses included in professional fees				0	$ 24,000
Consulting Agreement [Member] | Related Party [Member]
Accounts payable				47,500		41,500
Consulting Agreement [Member] | Donohoe Advisory Associates, LLC [Member]
Dividends, common stock				10,000
Consulting Agreement [Member] | Donohoe Advisory Associates, LLC [Member] | Consultant [Member]
Accounts payable				1,755
Retainer fees			$ 17,500
Professional fees				10,000
Consulting Agreement [Member] | Alpha IR Group, LLC [Member]
Agreed to payment of compensation		$ 50,000
Consulting Agreement [Member] | Alpha IR Group, LLC [Member] | Related Party [Member]
Accounts payable				73,999		$ 73,999
Employment Arrangement [Member] | Chief Executive Officer and Chairman [Member]
Capital				$ 8,000,000
Share based compensation description				(i) representing 1% of the Company’s fully diluted equity as of the payment date (the “Initial Equity Payment”) if the Company achieves a market capitalization of at least $250 million for sixty consecutive days during the Term (the “Initial Market Capitalization Target”); and (ii) representing the difference between 2% of the Company’s fully diluted equity as of the payment date and the amount of Initial Equity Payment (the “Subsequent Equity Payment” and, together with Initial Equity Payment, “Equity Payments”) if the Company achieves a market capitalization of at least $500 million for sixty consecutive days during the Term (the “Subsequent Market Capitalization Target” and, together with Initial Market Capitalization Target, “Market Capitalization Targets”), such that Mr. Pier has, in the aggregate, received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the date of payment of Subsequent Equity Payment.
Employment Arrangement [Member] | Deferred Bonus [Member] | Chief Executive Officer and Chairman [Member]
Share based compensation				$ 100,000